Evome Medical Technologies Bolsters Board of Directors With Appointment of Strategic Senior Healthcare Executives Wayne Anderson and Bill Garbarini, Appoints Kenneth Kashkin, MD, as Chairman
Evome Medical Technologies Bolsters Board of Directors With Appointment of Strategic Senior Healthcare Executives Wayne Anderson and Bill Garbarini, Appoints Kenneth Kashkin, MD, as Chairman
In addition, Kenneth Kashkin, MD, has been appointed Chairman of the Board of Directors. Dr. Kashkin is Board Certified in Internal Medicine, Neurology & Psychiatry with training at, and serving on, the faculties of the University of California, Los Angeles (UCLA) and Yale University Schools of Medicine. He has led development at divisions of Bayer, Abbott, Knoll/BASF Pharma and Baxter.NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the "Company" or "Evome") announces the appointment of two senior healthcare executives to its Board of Directors.
纽约，2024年2月15日（GLOBE NEWSWIRE）——Evome Medical Technologies Inc.（“公司” 或 “Evome”）宣布任命两名高级医疗保健高管为董事会成员。
Mr. Wayne Anderson, former President and CEO of Ferring Pharmaceuticals USA, has joined as a non-executive member of the Board of Directors.
美国辉凌制药公司前总裁兼首席执行官韦恩·安德森先生已加入董事会member 担任非执行董事。
Mr. Bill Garbarini, a former Ferring Pharmaceuticals USA executive and current COO of Conceivable Life Sciences, a venture backed in-vitro fertilization company, will also join as a non-executive member of the Board of Directors.
美国辉凌制药公司前高管、风险投资支持的体外受精公司Conceivable Life Sciences的现任首席运营官比尔·加巴里尼先生也将加入董事会担任非执行成员。
In addition, Kenneth Kashkin, MD, has been appointed Chairman of the Board of Directors. Dr. Kashkin is Board Certified in Internal Medicine, Neurology & Psychiatry with training at, and serving on, the faculties of the University of California, Los Angeles (UCLA) and Yale University Schools of Medicine. He has led development at divisions of Bayer, Abbott, Knoll/BASF Pharma and Baxter.
此外，医学博士肯尼思·卡什金被任命为董事会主席。卡什金博士获得内科、神经病学和精神病学委员会认证，曾在加州大学洛杉矶分校（UCLA）和耶鲁大学医学院接受过培训和任职。他曾领导拜耳、雅培、诺尔/巴斯夫制药和百特等部门的开发。
"Now that we have successfully executed on our turnaround plan, I am pleased to have Wayne and Bill join the Board," said Mike Seckler, CEO of Evome. "I worked with both of these talented and successful healthcare executives for many years while at Ferring and I am eager to benefit from their valuable guidance and expertise, particularly in the realms of product launch and commercialization. Dr. Kashkin's contributions will play a crucial role in advancing our innovation and development strategies, aligning with our vision to democratize our Biodex Brands. I can now say we have completed all of the necessary steps to transform our company. We have driven revenue growth, developed new products, cut costs and restructured our debt. The final step was to add some seasoned talent to our Board to assist us in driving shareholder value."
Evome首席执行官迈克·塞克勒说：“现在我们已经成功执行了周转计划，我很高兴韦恩和比尔加入Board。”“在辉凌工作期间，我与这两位才华横溢且成功的医疗保健高管合作了多年，我渴望从他们在产品发布和商业化领域的宝贵指导和专业知识中受益particularly。卡什金博士的贡献将在推进我们的创新和发展战略方面发挥至关重要的作用，这符合我们实现Biodex 品牌大众化的愿景。我现在可以说我们已经完成了公司转型的所有必要步骤。我们have 推动了收入增长，开发了新产品，削减了成本并重组了债务。最后一步是to 为我们的董事会增加一些经验丰富的人才，以帮助我们提高股东价值。”
For more information please contact:
欲了解更多信息，请联系：
Mike Seckler
Chief Executive Officer
Tel: 1 (800) 760-6826
Email: info@evomemedical.com
迈克·塞克勒
首席执行官
电话：1 (800) 760-6826
电子邮件：info@evomemedical.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
多伦多证券交易所风险交易所及其监管服务提供商（该术语在the 多伦多证券交易所风险投资交易所的policies 中定义）均不对本release 的充分性或准确性承担责任。
